What Tissue Regenix does

Tissue Regenix Group is a UK-headquartered regenerative medicine company that designs, manufactures, and distributes tissue-based medical devices and allografts for surgical specialists. The company was spun out of the University of Leeds in 2006 and operates a dual manufacturing footprint: a Leeds, UK facility (ISO 13485:2016 certified) producing porcine xenograft devices including the OrthoPure® XT Ligament Reconstruction Implant, and a San Antonio, Texas facility (formerly CellRight Technologies, acquired 2017) processing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under FDA registration and AATB accreditation. Core products span three franchises — DermaPure® decellularised dermal allografts (Standard, Non-Oriented, and Meshed 3:1 variants), OrthoPure® XT porcine ligament implants, and AmnioWorks™ human amniotic membrane — all built on two proprietary platform technologies: dCELL® (decellularisation preserving extracellular matrix) and BioRinse™ (complementary bone and soft tissue processing).

The commercial model is direct enterprise field sales to hospitals and medical professionals — primarily orthopaedic and sports medicine surgeons, wound care specialists, and pelvic floor surgeons — augmented by approved global distribution partners. End-markets include ACL reconstruction, wound care, burns, head/neck reconstruction, diabetic foot ulcers, and pelvic organ prolapse repair. Products carry CE marking, UKCA, FDA registration, and EU MDR certification for OrthoPure® XT. Revenue is generated through one-time sales of regulated medical device units under quotation-based procurement; no recurring subscription, licensing, or SaaS element is present. Pricing is not publicly disclosed.

Following the discovery of revenue misreporting and the restatement of 2024 financials in October 2025, the company entered acute financial distress, secured a $500K emergency overdraft from MidCap and £7.5M in convertible loan notes from Harwood Private Equity, and on January 7, 2026 delisted from London's AIM market and re-registered as a private limited company under new CEO/Chairman Jay LeCoque and CFO Kirsten Lund. A $2M cost reduction programme and revised commercial strategy are underway.

Name

Tissue Regenix

Legal name

Tissue Regenix Ltd

Website

https://tissueregenix.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

Tissue Regenix is a UK-based regenerative medicine company that develops and manufactures decellularised allograft and xenograft medical devices — including DermaPure, OrthoPure XT, and AmnioWorks — serving orthopaedic, sports medicine, wound care, and pelvic floor surgeons globally.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle) (HLAHAEAA)

Keywords

• Regenerative medicine devices
• Tissue allograft manufacturing
• Decellularised scaffold products
• Ligament reconstruction implants
• Dermal wound care grafts

Headquarters

HQ city

York

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Allograft and xenograft product sales: Sale of processed human tissue allografts (DermaPure®, AmnioWorks™) and xenograft products (OrthoPure® XT) to hospitals and medical professionals. Products are regulated medical devices distributed through direct sales and distribution partners.
2. HCT/P Products (US): Processing, storage, and distribution of Human Cells, Tissues, and Cellular and Tissue-Based Products regulated under FDA requirements at the San Antonio facility.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Tissue Regenix manufactures and distributes regenerative medical devices and tissue grafts using its proprietary dCELL® decellularisation and BioRinse™ processing platforms. The portfolio includes OrthoPure® XT (porcine tendon ligament reconstruction implant), DermaPure® (decellularised human dermal allograft) and AmnioWorks™ (acellular human amniotic membrane), produced at its San Antonio, Texas (human allograft) and Leeds, UK (porcine xenograft) facilities. Products are sold to hospitals and surgical specialists for wound care, orthopaedic, sports medicine and soft tissue reconstruction procedures.

Product overview

Tissue Regenix Group is a regenerative medicine company offering a portfolio of tissue-based medical devices and allografts powered by two proprietary technology platforms: dCELL® (decellularisation) and BioRinse™. The core product lineup includes OrthoPure® XT (a porcine-derived ligament reconstruction implant), DermaPure® family of decellularised dermal allografts (including Non-Oriented and Meshed variants), and AmnioWorks™ (human amniotic membrane for wound protection). The company operates dual manufacturing facilities in San Antonio, Texas (US, formerly CellRight Technologies) processing HCT/Ps under FDA regulation, and Leeds, UK producing porcine tissue medical devices including OrthoPure® XT under ISO 13485 certification.

Differentiator

Problem solved

Functional benefit

Brands

• AmnioWorks™: Birth tissue product derived from human amniotic membrane following live birth from volunteer donors. Available in multiple patch and disc sizes with a 5-year shelf life.
• DermaPure®
• OrthoPure® XT
• dCELL®
• BioRinse™

Products and services

• OrthoPure® XT
• DermaPure®
• AmnioWorks™

Quantifiable outcome

• Estimated 1.5 million ACL reconstructions per year globally, with OrthoPure® XT addressing limitations of autograft and allograft options
• +2 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered supporting.

• University of LeedssupportingStrategic or Co-development PartnerTissue Regenix was spun out of the University of Leeds in 2006, maintaining strong connections to the university. The UK facility acts as the R&D hub for potential future portfolio developments.
• American Association of Tissue Banks (AATB)supportingOthersAATB-accredited organisation (#00212/4). The US facility operates in compliance with AATB Standards and other international requirements.

Scale indicators4 records

Recent moves9 records

Expansion highlights4 records

Direct peers

• Organogenesis Holdings: Organogenesis is a direct competitor in regenerative skin and wound care with products like Apligraf® and Dermagraft®, addressing similar chronic wound, DFU/VLU, and surgical reconstruction indications as Tissue Regenix's DermaPure® family. Both companies sell decellularised/cellular biologic matrices through hospital and wound care channels.
• Vericel Corporation: Vericel is a direct peer in regenerative medicine with autologous and allogeneic cell-based cartilage repair products (MACI, Carticel). They compete with Tissue Regenix in the orthopaedic regenerative medicine space, particularly in sports medicine indications like cartilage and ligament restoration.
• AlloSource: AlloSource is a non-profit tissue bank that directly competes with Tissue Regenix's CellRight Technologies–derived allograft business, offering dermal, bone, and sports medicine allografts to hospitals and distributors. Their product portfolio overlaps substantially with DermaPure® and the BioRinse™ bone line.
• MiMedx Group: MiMedx is a direct competitor in regenerative medicine, commercialising amniotic membrane products (e.g., EpiFix®, AmnioFix®) that directly overlap Tissue Regenix's AmnioWorks™ and overlap with wound care indications served by DermaPure®. Both companies focus on placental tissue–based allografts processed under HCT/P frameworks.
• MTF Biologics: MTF Biologics is one of the largest tissue banks in the US and a direct competitor across allograft portfolios (dermal, bone, sports medicine). They share Tissue Regenix's AATB-accredited, FDA-registered operating model and compete head-to-head in BioRinse-processed bone and soft tissue allografts as well as dermal matrices.

Broad incumbents

• Arthrex: Arthrex is the dominant incumbent in sports medicine/orthopaedics with biologic and graft products (e.g., BioCartilage®, allograft tendons for ACL reconstruction). They compete with OrthoPure® XT in ACL reconstruction and broader sports medicine soft tissue repair, though their portfolio spans much more than biologics.
• Smith+Nephew: Smith+Nephew is a broad incumbent with overlapping wound management (e.g., PICO single-use NPWT) and orthopaedic sports medicine portfolios, including regenerative cartilage products (MACI via the Osiris acquisition). They compete with Tissue Regenix on wound care and orthobiologic scaffolds but at a much larger scale and with broader indication coverage.
• Stryker Corporation: Stryker is a broad incumbent that competes with Tissue Regenix in orthopaedics, sports medicine, and surgical biologics through its Mako/MAKOplasty and biologics portfolio. While they don't directly overlap with decellularised xenografts, they are a large competitor for hospital orthopaedic procurement budgets that Tissue Regenix must win against.
• Integra LifeSciences: Integra LifeSciences is a broad incumbent in regenerative tissue technologies (Integra® Dermal Regeneration Template) and surgical implants. They compete with Tissue Regenix across dermal regeneration and orthopaedic soft tissue, but at a much larger scale and broader portfolio including neurosurgery and ENT.
• CONMED Corporation: CONMED is a broad incumbent in orthopaedic and sports medicine surgical devices with biologic and allograft offerings that overlap with OrthoPure® XT and BioRinse™ bone products. They serve similar surgical specialties (orthopaedics, podiatry, sports medicine) through hospital and ambulatory surgery center channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/tissue_regenix
• LinkedInlinkedin.com/company/tissue-regenix-ltd

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tissue Regenix